Strategy for prevention of hip fractures in patients with Parkinson&rsquo;s disease

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

182

HTML

2972

Tables (1-2)

Sum=3154

Sep 18, 2012 (publication date) through Sep 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Orthop. Sep 18, 2012; 3(9): 137-141
Published online Sep 18, 2012. doi: 10.5312/wjo.v3.i9.137

Table 2 Efficacy of interventions against hip fractures in patients with Parkinson’s disease

Interventions	Relative risk (95% confidence interval)
	ITT set	PPS
Sunlight exposure[12]	0.27 (0.08, 0.96)	0.27 (0.08, 0.95)
Menatetrenone[13]	0.13 (0.02, 0.97)	0.12 (0.02, 0.93)
Alendronate (Daily)[14]	0.29 (0.10, 0.85)	0.28 (0.10, 0.83)
Risedronate (Daily)[15]	0.33 (0.09, 1.20)	0.34 (0.09, 1.21)
Risedronate (Weekly)[16]	0.20 (0.06, 0.68)	0.20 (0.06, 0.66)

ITT: Intention-to-treat, PPS: Per-protocol set.

Citation: Iwamoto J, Sato Y, Takeda T, Matsumoto H. Strategy for prevention of hip fractures in patients with Parkinson’s disease. World J Orthop 2012; 3(9): 137-141
URL: https://www.wjgnet.com/2218-5836/full/v3/i9/137.htm
DOI: https://dx.doi.org/10.5312/wjo.v3.i9.137